|
US5472693A
(en)
*
|
1993-02-16 |
1995-12-05 |
The Dow Chemical Company |
Family of anti-carcinoembryonic antigen chimeric antibodies
|
|
TW458985B
(en)
*
|
1993-05-31 |
2001-10-11 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human antibody against human interleukin-6
|
|
EP0714439B1
(en)
*
|
1993-08-24 |
2003-04-23 |
Nissin Shokuhin Kabushiki Kaisha |
Recombinant humanized anti-human immunodeficiency virus antibody
|
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
EP0729976A1
(en)
*
|
1993-11-19 |
1996-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human medulloblastomatous cell
|
|
WO1995029690A1
(en)
*
|
1994-04-29 |
1995-11-09 |
The Trustees Of The University Of Pennsylvania |
Biologically active peptides and methods of identifying the same
|
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
|
PT783893E
(pt)
|
1994-10-07 |
2012-05-24 |
Chugai Pharmaceutical Co Ltd |
Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
|
|
HU225392B1
(en)
*
|
1994-10-21 |
2006-11-28 |
Chugai Pharmaceutical Co Ltd |
Use of an antibody againts interleukin-6-receptor for producing a pharmaceutical composition for treating anemia and cachexia caused by il-6 production
|
|
AU693318B2
(en)
*
|
1995-02-13 |
1998-06-25 |
Chugai Seiyaku Kabushiki Kaisha |
Muscle protein decomposition inhibitor containing IL-6 receptor antibody
|
|
US6692742B1
(en)
|
1996-06-27 |
2004-02-17 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for myeloma to be used together with nitrogen mustard antitumor agents
|
|
HUP9904177A3
(en)
|
1996-09-26 |
2001-10-29 |
Chugai Pharmaceutical Co Ltd |
Antibody against human parathormone related peptides
|
|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
|
CN1191855C
(zh)
|
1997-02-12 |
2005-03-09 |
中外制药株式会社 |
淋巴细胞系肿瘤的治疗剂
|
|
EP0983767B1
(en)
|
1997-03-21 |
2008-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives or remedies for the treatment of multiple sclerosis containing antagonist anti-IL-6-receptor antibodies
|
|
IL132896A0
(en)
|
1997-05-15 |
2001-03-19 |
Chugai Pharmaceutical Co Ltd |
Cachexia remedy
|
|
US20020187150A1
(en)
*
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
|
KR20040024561A
(ko)
*
|
1997-08-15 |
2004-03-20 |
츄가이 세이야꾸 가부시키가이샤 |
항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
|
|
DK1074268T3
(da)
|
1998-03-17 |
2008-04-28 |
Chugai Pharmaceutical Co Ltd |
IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
|
|
PL343322A1
(en)
|
1998-04-03 |
2001-08-13 |
Chugai Pharmaceutical Co Ltd |
Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
|
|
WO2000010607A1
(en)
*
|
1998-08-24 |
2000-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives or remedies for pancreatitis containing il-6 antagonists as the active ingredient
|
|
MXPA01005275A
(es)
|
1998-11-27 |
2003-06-06 |
Darwin Discovery Ltd |
Composiciones y metodos para aumentar la mineralizacion de huesos.
|
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
|
AU7078200A
(en)
*
|
1999-08-27 |
2001-03-26 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
|
|
ATE498305T1
(de)
|
1999-10-01 |
2011-03-15 |
Chugai Pharmaceutical Co Ltd |
Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
|
|
GB0002666D0
(en)
|
2000-02-04 |
2000-03-29 |
Univ London |
Blockade of voltage dependent sodium channels
|
|
AU2001252618A1
(en)
|
2000-04-28 |
2001-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors
|
|
AU2001277781A1
(en)
|
2000-08-11 |
2002-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing preparations
|
|
WO2002032374A2
(en)
*
|
2000-10-18 |
2002-04-25 |
Immunex Corporation |
Methods for treating il-18 mediated disorders
|
|
CN1308447C
(zh)
|
2000-10-20 |
2007-04-04 |
中外制药株式会社 |
低分子化的激动剂抗体
|
|
EP1327681A4
(en)
|
2000-10-20 |
2004-09-01 |
Chugai Pharmaceutical Co Ltd |
Degraded agonist antibodies
|
|
CN1308448C
(zh)
|
2000-10-20 |
2007-04-04 |
中外制药株式会社 |
低分子化的tpo激动剂抗体
|
|
EP1334731B1
(en)
|
2000-10-25 |
2008-02-27 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
|
|
WO2002036164A1
(en)
*
|
2000-10-27 |
2002-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
|
|
AU2000279625A1
(en)
*
|
2000-10-27 |
2002-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
|
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
|
US20030044406A1
(en)
*
|
2001-03-02 |
2003-03-06 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
|
|
ES2869895T3
(es)
|
2001-03-09 |
2021-10-26 |
Chugai Pharmaceutical Co Ltd |
Método de purificación de proteínas
|
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
|
EP1382964A4
(en)
|
2001-04-17 |
2009-06-10 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR TENSID QUANTIFICATION
|
|
US7589180B2
(en)
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
*
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
ES2536709T3
(es)
*
|
2002-02-14 |
2015-05-27 |
Chugai Seiyaku Kabushiki Kaisha |
Utilización de ácido acético para eliminar los problemas inducidos por el ión Fe en las formulaciones de anticuerpos anti-HM1.24 o anti-IL6R
|
|
GB0208041D0
(en)
*
|
2002-04-08 |
2002-05-22 |
Lonza Biologics Plc |
Method of culturing animal cells
|
|
WO2004022597A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
|
|
AU2003235948A1
(en)
*
|
2002-04-25 |
2003-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
Remedy for lung cancer
|
|
NZ556507A
(en)
*
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
|
JP4489591B2
(ja)
|
2002-08-27 |
2010-06-23 |
中外製薬株式会社 |
タンパク質溶液製剤の安定化方法
|
|
SI1561756T1
(sl)
|
2002-09-11 |
2016-02-29 |
Chugai Seiyaku Kabushiki Kaisha |
Postopek čiščenja proteinov
|
|
JP4555924B2
(ja)
*
|
2003-02-24 |
2010-10-06 |
中外製薬株式会社 |
インターロイキン−６アンタゴニストを含有する脊髄損傷治療剤
|
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
CA2529623A1
(en)
*
|
2003-06-16 |
2005-02-17 |
Celltech R & D, Inc. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
|
ATE490787T1
(de)
|
2003-07-15 |
2010-12-15 |
Chugai Pharmaceutical Co Ltd |
Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
|
|
MXPA06003768A
(es)
|
2003-10-17 |
2006-06-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapeutico para el mesotelioma.
|
|
AU2004295590B2
(en)
|
2003-12-03 |
2010-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Expression systems using mammalian beta-actin promoter
|
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
|
US8617550B2
(en)
|
2003-12-19 |
2013-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of vasculitis with IL-6 antagonist
|
|
ES2341461T5
(es)
*
|
2004-02-11 |
2014-10-29 |
Warner-Lambert Company Llc |
Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6
|
|
WO2005079479A2
(en)
*
|
2004-02-17 |
2005-09-01 |
Absalus, Inc. |
Super-humanized antibodies against respiratory syncytial virus
|
|
US7767792B2
(en)
*
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
|
EP1728801A4
(en)
*
|
2004-03-24 |
2009-10-21 |
Chugai Pharmaceutical Co Ltd |
SUBTYP OF A HUMANIZED ANTIBODY AGAINST THE INTERLEUKIN-6 RECEPTOR
|
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
GB0410627D0
(en)
*
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
|
JPWO2006046661A1
(ja)
*
|
2004-10-28 |
2008-05-22 |
国立大学法人大阪大学 |
インターロイキン−６阻害剤
|
|
US9714410B2
(en)
|
2005-01-05 |
2017-07-25 |
Chugai Seiyaku Kabushiki Kaisha |
Cell culture method and utilization of the same
|
|
HRP20110349T1
(hr)
*
|
2005-02-28 |
2011-07-31 |
Eisai R&D Management Co. |
Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma
|
|
US9493569B2
(en)
|
2005-03-31 |
2016-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Structural isomers of sc(Fv)2
|
|
US10011858B2
(en)
|
2005-03-31 |
2018-07-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
CN101262885B
(zh)
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
含有sc(Fv)2的药物组合物
|
|
CN101237890A
(zh)
|
2005-06-10 |
2008-08-06 |
中外制药株式会社 |
含有葡甲胺的蛋白质制剂的稳定剂及其利用
|
|
JP2009505640A
(ja)
*
|
2005-08-11 |
2009-02-12 |
− ロジャーズ、アルピ マトシアン |
自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
|
|
CN101330929B
(zh)
|
2005-10-14 |
2014-03-05 |
学校法人福冈大学 |
胰岛移植中的移植胰岛障碍抑制剂
|
|
CN101330930B
(zh)
|
2005-10-21 |
2011-11-23 |
中外制药株式会社 |
心脏病治疗剂
|
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
WO2007055378A1
(ja)
|
2005-11-14 |
2007-05-18 |
Cell Signals Inc. |
調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
|
|
AR057582A1
(es)
*
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
|
TW200803894A
(en)
*
|
2005-11-25 |
2008-01-16 |
Univ Keio |
Prostate cancer therapeutic agents
|
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
|
CA2637917C
(en)
|
2006-01-27 |
2015-11-24 |
Keio University |
Therapeutic agents for diseases involving choroidal neovascularization
|
|
WO2007108505A1
(ja)
|
2006-03-22 |
2007-09-27 |
Chugai Seiyaku Kabushiki Kaisha |
エリスロポエチン溶液製剤
|
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
ES2892925T3
(es)
|
2006-03-31 |
2022-02-07 |
Chugai Pharmaceutical Co Ltd |
Métodos para controlar la farmacocinética en sangre de anticuerpos
|
|
JP5754875B2
(ja)
|
2006-04-07 |
2015-07-29 |
国立大学法人大阪大学 |
筋再生促進剤
|
|
US8741643B2
(en)
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
|
AR061115A1
(es)
*
|
2006-05-25 |
2008-08-06 |
Glaxo Group Ltd |
Anticuerpos anti- interleuquina 18 (il-18)
|
|
ATE537190T1
(de)
*
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
JP2009539403A
(ja)
|
2006-06-13 |
2009-11-19 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
癌を診断および処置するための組成物および方法
|
|
ES2405618T3
(es)
|
2006-06-21 |
2013-05-31 |
Oncotherapy Science, Inc. |
Anticuerpos monoclonales dirigidos a tumores para FZD10 y usos de los mismos
|
|
AU2007285695B2
(en)
|
2006-08-18 |
2012-05-24 |
Ablynx N.V. |
Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
|
|
US20080081041A1
(en)
*
|
2006-09-29 |
2008-04-03 |
Jeffrey Nemeth |
Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
|
|
CA2675625C
(en)
|
2007-01-23 |
2016-09-13 |
Shinshu University |
Chronic rejection inhibitor
|
|
WO2008091641A2
(en)
|
2007-01-24 |
2008-07-31 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
MX338185B
(es)
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
|
PT3187506T
(pt)
|
2007-05-21 |
2019-04-24 |
Alderbio Holdings Llc |
Anticorpos contra il-6 e sua utilização
|
|
WO2008144757A1
(en)
*
|
2007-05-21 |
2008-11-27 |
Alder Biopharmaceuticals, Inc. |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US8062864B2
(en)
*
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US7906117B2
(en)
*
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
|
JP5142265B2
(ja)
*
|
2007-05-28 |
2013-02-13 |
独立行政法人産業技術総合研究所 |
抗モータリン抗体のパラトープ及びエピトープ
|
|
US9080145B2
(en)
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
|
US20100129355A1
(en)
*
|
2007-07-26 |
2010-05-27 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
|
WO2009018453A1
(en)
|
2007-07-31 |
2009-02-05 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells
|
|
CA2696360C
(en)
|
2007-08-14 |
2018-11-20 |
Ludwig Institute For Cancer Research |
Monoclonal antibody targeting the egfr receptor and uses thereof
|
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
|
RU2510400C9
(ru)
|
2007-09-26 |
2014-07-20 |
Чугаи Сейяку Кабусики Кайся |
Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
|
|
PE20090711A1
(es)
|
2007-09-26 |
2009-07-15 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo mutante
|
|
WO2009041621A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
抗il-6レセプター抗体
|
|
KR101601986B1
(ko)
|
2007-10-02 |
2016-03-17 |
추가이 세이야쿠 가부시키가이샤 |
인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
|
|
KR101558009B1
(ko)
*
|
2007-10-15 |
2015-10-19 |
추가이 세이야쿠 가부시키가이샤 |
항체의 제조 방법
|
|
KR101706928B1
(ko)
|
2007-11-27 |
2017-02-27 |
라이프스캔, 인코포레이티드 |
인간 배아 줄기 세포의 분화
|
|
JP5682995B2
(ja)
*
|
2007-12-05 |
2015-03-11 |
中外製薬株式会社 |
抗ｎｒ１０抗体、およびその利用
|
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
WO2009095489A2
(en)
*
|
2008-02-01 |
2009-08-06 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
|
|
BRPI0908033A2
(pt)
|
2008-02-21 |
2015-08-04 |
Centocor Ortho Biotech Inc |
Método placas de superfície modificada e composições para adesão, cultura e desprendimento de célula
|
|
SI2275443T1
(sl)
*
|
2008-04-11 |
2016-03-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-vezavna molekula, ki se je sposobna ponovljivo vezati na dve ali več antigenskih molekul
|
|
US8623648B2
(en)
|
2008-04-24 |
2014-01-07 |
Janssen Biotech, Inc. |
Treatment of pluripotent cells
|
|
NZ588554A
(en)
*
|
2008-04-29 |
2013-03-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
MX2010012031A
(es)
*
|
2008-05-13 |
2011-01-20 |
Novimmune Sa |
Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
|
|
AR072001A1
(es)
|
2008-06-03 |
2010-07-28 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
KR101665729B1
(ko)
|
2008-06-05 |
2016-10-12 |
국립연구개발법인 고쿠리츠간켄큐센터 |
신경침윤 억제제
|
|
US8188235B2
(en)
|
2008-06-18 |
2012-05-29 |
Pfizer Inc. |
Antibodies to IL-6 and their uses
|
|
JP5734183B2
(ja)
|
2008-06-30 |
2015-06-17 |
ヤンセン バイオテツク，インコーポレーテツド |
多能性幹細胞の分化
|
|
US9132189B2
(en)
|
2008-07-08 |
2015-09-15 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
|
JP5560270B2
(ja)
|
2008-07-08 |
2014-07-23 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
|
|
US8822645B2
(en)
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
US9234178B2
(en)
|
2008-10-31 |
2016-01-12 |
Janssen Biotech, Inc. |
Differentiation of human pluripotent stem cells
|
|
AU2009316583B2
(en)
|
2008-11-20 |
2016-04-21 |
Janssen Biotech, Inc. |
Methods and compositions for cell attachment and cultivation on planar substrates
|
|
CN102307991B
(zh)
|
2008-11-20 |
2017-08-15 |
森托科尔奥索生物科技公司 |
微载体上的多能干细胞培养
|
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
|
US8323649B2
(en)
*
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
|
US9452227B2
(en)
*
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
AU2010233658B2
(en)
|
2009-04-10 |
2013-11-28 |
Ablynx Nv |
Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
|
|
WO2010115995A2
(en)
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
|
SG175426A1
(en)
*
|
2009-05-01 |
2011-12-29 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
BRPI1011145A2
(pt)
|
2009-05-15 |
2016-03-15 |
Chugai Pharmaceutical Co Ltd |
anticorpo anti-axl
|
|
BR112012001480A2
(pt)
|
2009-07-20 |
2015-09-01 |
Janssen Biotech Inc |
Diferenciação de células-tronco embriônicas humanas
|
|
SG178190A1
(en)
|
2009-07-31 |
2012-03-29 |
Shin Maeda |
Cancer metastasis inhibitor
|
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
JP2013507928A
(ja)
*
|
2009-10-15 |
2013-03-07 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
SG10201510640QA
(en)
|
2009-10-26 |
2016-01-28 |
Hoffmann La Roche |
Method For The Production Of A Glycosylated Immunoglobulin
|
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
|
EP2504030A4
(en)
|
2009-11-24 |
2013-06-26 |
Alderbio Holdings Llc |
IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
|
|
CN102781964B
(zh)
|
2009-12-28 |
2015-11-25 |
肿瘤疗法科学股份有限公司 |
抗cdh3抗体及其用途
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
EP2523682B1
(en)
*
|
2010-01-13 |
2015-12-16 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
WO2011109279A2
(en)
|
2010-03-01 |
2011-09-09 |
Centocor Ortho Biotech Inc. |
Methods for purifying cells derived from pluripotent stem cells
|
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
|
JP5845171B2
(ja)
|
2010-03-04 |
2016-01-20 |
大日本住友製薬株式会社 |
炎症性腸疾患用薬剤
|
|
EP3372617B1
(en)
|
2010-04-02 |
2024-07-24 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
WO2011128096A1
(en)
|
2010-04-16 |
2011-10-20 |
Roche Diagnostics Gmbh |
Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
|
|
RU2663339C1
(ru)
|
2010-05-12 |
2018-08-03 |
Янссен Байотек, Инк. |
Дифференцирование эмбриональных стволовых клеток человека
|
|
SMT202000095T1
(it)
|
2010-05-14 |
2020-03-13 |
Amgen Inc |
Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
|
|
EP4115906A1
(en)
|
2010-05-28 |
2023-01-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antitumor t cell response enhancer
|
|
JP5904552B2
(ja)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
膵癌治療剤
|
|
JPWO2011152503A1
(ja)
|
2010-06-02 |
2013-08-01 |
大日本住友製薬株式会社 |
自己免疫疾患またはアレルギー疾患の治療剤
|
|
CA2801107A1
(en)
|
2010-06-07 |
2011-12-15 |
F. Hoffman-La Roche Ag |
Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
|
|
AR081434A1
(es)
*
|
2010-06-10 |
2012-08-29 |
Lilly Co Eli |
Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
|
|
SG188190A1
(en)
|
2010-08-03 |
2013-04-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
RU2620938C2
(ru)
|
2010-08-31 |
2017-05-30 |
Янссен Байотек, Инк. |
Дифференцирование эмбриональных стволовых клеток человека
|
|
ES2737960T3
(es)
|
2010-10-01 |
2020-01-17 |
Modernatx Inc |
Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos
|
|
CN103298489A
(zh)
|
2010-10-29 |
2013-09-11 |
伊缪诺金公司 |
新型egfr结合分子及其免疫偶联物
|
|
JP5828902B2
(ja)
|
2010-10-29 |
2015-12-09 |
イミュノジェン， インコーポレイテッド |
非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
|
|
WO2012064627A2
(en)
|
2010-11-08 |
2012-05-18 |
Genentech, Inc. |
Subcutaneously administered anti-il-6 receptor antibody
|
|
PH12013500974A1
(en)
|
2010-11-17 |
2013-07-08 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
CA2818814A1
(en)
|
2010-11-23 |
2012-05-31 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of anemia
|
|
JP6030452B2
(ja)
|
2010-11-30 |
2016-11-24 |
中外製薬株式会社 |
複数分子の抗原に繰り返し結合する抗原結合分子
|
|
MX385311B
(es)
|
2011-01-28 |
2025-03-18 |
Sanofi Biotechnology |
Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
|
|
KR20200103845A
(ko)
|
2011-02-25 |
2020-09-02 |
추가이 세이야쿠 가부시키가이샤 |
ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
|
|
US9133272B2
(en)
|
2011-03-01 |
2015-09-15 |
Amgen Inc. |
Bispecific binding agents
|
|
CN103517920B
(zh)
|
2011-03-25 |
2018-04-17 |
安进公司 |
抗硬化蛋白(sclerostin)抗体晶体及其制剂
|
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
|
EP3150632B1
(en)
|
2011-06-10 |
2020-04-08 |
Her Majesty The Queen in right of Canada, as represented by the Minister of National Defence |
Anti-ricin antibodies and uses thereof
|
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
|
CA3132298A1
(en)
|
2011-06-28 |
2013-01-03 |
Inhibrx, Inc. |
Serpin fusion polypeptides and methods of use thereof
|
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
|
EP2739652B1
(en)
|
2011-08-04 |
2017-04-05 |
Medizinische Universität Innsbruck |
Cahgt1p inhibitors for use in the treatment of candidiasis
|
|
HUE039786T2
(hu)
|
2011-08-04 |
2019-02-28 |
Amgen Inc |
Csonthiány-defektusok kezelési módszere
|
|
MY182178A
(en)
|
2011-09-01 |
2021-01-18 |
Chugai Pharmaceutical Co Ltd |
Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3311837A1
(en)
|
2011-09-23 |
2018-04-25 |
Ablynx NV |
Prolonged inhibition of interleukin-6 mediated signaling
|
|
DE102011083811A1
(de)
*
|
2011-09-30 |
2013-04-04 |
Airbus Operations Gmbh |
Sitzvorrichtung für ein Luft- oder Raumfahrzeug
|
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
CN110511939A
(zh)
|
2011-10-03 |
2019-11-29 |
现代泰克斯公司 |
修饰的核苷、核苷酸和核酸及其用途
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
WO2013059548A1
(en)
|
2011-10-19 |
2013-04-25 |
Sanofi |
Compositions and methods for treating cancer using jak2 inhibitor
|
|
CN104203982B
(zh)
|
2011-10-28 |
2018-08-31 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
|
JO3370B1
(ar)
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
CA2856411A1
(en)
|
2011-11-21 |
2013-05-30 |
Immunogen, Inc. |
Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
|
|
ES2719108T3
(es)
|
2011-11-30 |
2019-07-08 |
Abbvie Biotechnology Ltd |
Vectores y células hospedadoras que comprenden un promotor de SV40 modificado para la expresión de proteínas
|
|
HK1203372A1
(en)
*
|
2011-12-13 |
2015-10-30 |
Nordic Nanovector Asa |
Chimeric therapeutic anti - cd37 antibodie hh1
|
|
HK1203077A1
(en)
|
2011-12-16 |
2015-10-16 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
CN105143446B
(zh)
|
2011-12-22 |
2020-11-03 |
詹森生物科技公司 |
人胚胎干细胞分化成单一激素胰岛素阳性细胞
|
|
US9657090B2
(en)
|
2011-12-28 |
2017-05-23 |
Amgen Inc. |
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
|
|
US9120870B2
(en)
|
2011-12-30 |
2015-09-01 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-13 and IL-17
|
|
KR102153374B1
(ko)
|
2012-03-15 |
2020-09-10 |
얀센 바이오테크 인코포레이티드 |
인간 항-cd27 항체, 방법 및 용도
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
CA2868434A1
(en)
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Modified polynucleotides
|
|
ES2599386T3
(es)
|
2012-04-17 |
2017-02-01 |
F. Hoffmann-La Roche Ag |
Método para la expresión de polipéptidos usando ácidos nucleicos modificados
|
|
KR101510302B1
(ko)
*
|
2012-05-11 |
2015-04-10 |
가톨릭대학교 산학협력단 |
Ｉｌ-６ 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제
|
|
KR101510830B1
(ko)
|
2012-05-11 |
2015-04-10 |
가톨릭대학교 산학협력단 |
생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법
|
|
KR101510831B1
(ko)
*
|
2012-05-11 |
2015-04-10 |
가톨릭대학교 산학협력단 |
항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
|
|
SG10201610313WA
(en)
|
2012-06-08 |
2017-02-27 |
Janssen Biotech Inc |
Differentiation of human embryonic stem cells into pancreatic endocrine cells
|
|
EP3626267A1
(en)
|
2012-07-05 |
2020-03-25 |
UCB Pharma, S.A. |
Treatment for bone diseases
|
|
CN104797132B
(zh)
|
2012-09-13 |
2017-06-30 |
中外制药株式会社 |
基因敲入非人动物
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
KR20210111353A
(ko)
|
2012-11-01 |
2021-09-10 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
DK2922554T3
(en)
|
2012-11-26 |
2022-05-23 |
Modernatx Inc |
Terminalt modificeret rna
|
|
DK2938724T3
(da)
|
2012-12-31 |
2020-12-14 |
Janssen Biotech Inc |
Dyrkning af humane embryonale stamceller ved luft-væskegrænsefladen til differentiering til endokrine pankreasceller
|
|
JP6557147B2
(ja)
|
2012-12-31 |
2019-08-07 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
|
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
|
US10377989B2
(en)
|
2012-12-31 |
2019-08-13 |
Janssen Biotech, Inc. |
Methods for suspension cultures of human pluripotent stem cells
|
|
TW201512219A
(zh)
|
2013-03-15 |
2015-04-01 |
Abbvie Inc |
針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
ES2774976T3
(es)
|
2013-04-29 |
2020-07-23 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
WO2014200018A1
(ja)
|
2013-06-11 |
2014-12-18 |
独立行政法人 国立精神・神経医療研究センター |
再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
|
|
KR102248581B1
(ko)
|
2013-07-04 |
2021-05-06 |
에프. 호프만-라 로슈 아게 |
혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석
|
|
CA2925256C
(en)
|
2013-09-27 |
2023-08-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
CN105980556B
(zh)
|
2013-12-26 |
2020-10-09 |
田边三菱制药株式会社 |
人抗il－33中和单克隆抗体
|
|
EP4671270A2
(en)
|
2013-12-27 |
2025-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR THE PURIFICATION OF ANTIBODY WITH A LOW ISOELECTRIC POINT
|
|
EP2898896A1
(en)
|
2014-01-22 |
2015-07-29 |
Université Pierre et Marie Curie (Paris 6) |
Agents for use in the treatment of retinal inflammation
|
|
WO2015116852A1
(en)
|
2014-01-29 |
2015-08-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating rheumatoid arthritis by administering an il-6r antibody
|
|
AR099812A1
(es)
|
2014-03-21 |
2016-08-17 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
US10006006B2
(en)
|
2014-05-16 |
2018-06-26 |
Janssen Biotech, Inc. |
Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
|
|
EP4056993A1
(en)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring viscosity of protein solution
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
JP2017534617A
(ja)
|
2014-10-21 |
2017-11-24 |
アブリンクス エン．ヴェー． |
Ｉｌ−６ｒ関連疾患の処置
|
|
IL251822B2
(en)
|
2014-10-29 |
2023-03-01 |
Teva Pharmaceuticals Australia Pty Ltd |
Variants of interferon alpha-2-b
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
|
US11384350B2
(en)
|
2014-12-15 |
2022-07-12 |
The Regents Of The University Of California |
Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
|
|
PL3240805T3
(pl)
|
2014-12-15 |
2025-05-05 |
The Regents Of The University Of California |
Dwuswoisty chimeryczny receptor antygenu z bramką alternatywy, reaktywny wobec cd19 oraz cd20
|
|
UA128712C2
(uk)
|
2014-12-19 |
2024-10-09 |
Чугаі Сейяку Кабусікі Кайся |
Антитіла проти c5 та способи застосування
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
KR20240090831A
(ko)
|
2015-02-05 |
2024-06-21 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
|
PL3263132T3
(pl)
|
2015-02-27 |
2024-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Kompozycja do leczenia chorób związanych z il-6
|
|
AR104050A1
(es)
|
2015-03-26 |
2017-06-21 |
Chugai Pharmaceutical Co Ltd |
Proceso de producción con iones de cobre controlados
|
|
EP3279216A4
(en)
|
2015-04-01 |
2019-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
|
|
JP6875683B2
(ja)
|
2015-05-19 |
2021-05-26 |
国立研究開発法人国立精神・神経医療研究センター |
多発性硬化症（ｍｓ）患者の新規治療適用判断方法
|
|
EP3305325B1
(en)
|
2015-06-04 |
2025-07-30 |
National Center of Neurology and Psychiatry |
Mental illness therapeutic agent having il-6 inhibitor as active ingredient
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
US10772956B2
(en)
|
2015-08-18 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
|
|
MX2018005589A
(es)
|
2015-11-03 |
2018-11-09 |
Regeneron Pharma |
Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
|
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
|
WO2017147169A1
(en)
|
2016-02-22 |
2017-08-31 |
Ohio State Innovation Foundation |
Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
|
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
CA3016424A1
(en)
|
2016-03-14 |
2017-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
|
MA44780A
(fr)
|
2016-04-28 |
2019-03-06 |
Chugai Pharmaceutical Co Ltd |
Préparation contenant un anticorps
|
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
CN109963590B
(zh)
|
2016-09-02 |
2024-03-15 |
加利福尼亚大学董事会 |
涉及白介素-6受体α结合单链可变片段的方法和组合物
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
RU2019112680A
(ru)
|
2016-09-27 |
2020-10-29 |
Фрезениус Каби Дойчланд Гмбх |
Жидкая фармацевтическая композиция
|
|
KR102051177B1
(ko)
*
|
2016-10-19 |
2019-12-17 |
주식회사 엘지화학 |
전압 분배를 이용한 스위치 진단 장치 및 방법
|
|
JP2019536761A
(ja)
|
2016-10-31 |
2019-12-19 |
フレゼニウス カービ ドイチュラント ゲーエムベーハー |
液体医薬組成物
|
|
WO2018156180A1
(en)
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
|
WO2018170405A1
(en)
|
2017-03-17 |
2018-09-20 |
Ohio State Innovation Foundation |
Nanoparticles for delivery of chemopreventive agents
|
|
JP7185884B2
(ja)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
|
|
CN107098969B
(zh)
*
|
2017-06-28 |
2018-10-12 |
武汉波睿达生物科技有限公司 |
一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
|
|
CN115920041A
(zh)
|
2017-08-31 |
2023-04-07 |
田边三菱制药株式会社 |
含有il-33拮抗剂的子宫内膜异位症治疗剂
|
|
AU2018331725A1
(en)
|
2017-09-13 |
2020-04-23 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-6R antibody and antigen binding fragment thereof and medical use
|
|
EP3698808B1
(en)
|
2017-10-20 |
2025-01-01 |
Hyogo College Of Medicine |
Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
|
US12421322B2
(en)
|
2017-11-01 |
2025-09-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody variant and isoform with lowered biological activity
|
|
TWI822728B
(zh)
|
2018-01-31 |
2023-11-21 |
加藤元一 |
含有il-6抑制劑的哮喘治療劑
|
|
WO2019177543A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
|
MX2020010092A
(es)
|
2018-03-30 |
2020-10-28 |
Amgen Inc |
Variantes de anticuerpo c-terminales.
|
|
WO2019225568A1
(ja)
|
2018-05-21 |
2019-11-28 |
中外製薬株式会社 |
ガラス容器に封入された凍結乾燥製剤
|
|
CN115636141A
(zh)
|
2018-05-28 |
2023-01-24 |
中外制药株式会社 |
填充喷嘴
|
|
WO2020047029A1
(en)
|
2018-08-29 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having rheumatoid arthritis
|
|
AU2020205951A1
(en)
*
|
2019-01-07 |
2021-07-22 |
Hunan Siweikang Therapeutics Co. Ltd |
Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
|
|
TWI860325B
(zh)
|
2019-01-31 |
2024-11-01 |
法商賽諾菲生物技術公司 |
用於治療幼年原發性關節炎之組成物及方法
|
|
JPWO2020202839A1
(enExample)
|
2019-03-29 |
2020-10-08 |
|
|
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
|
TW202509054A
(zh)
|
2019-04-10 |
2025-03-01 |
日商中外製藥股份有限公司 |
Fc區域改變抗體的純化方法
|
|
TWI868126B
(zh)
|
2019-04-17 |
2025-01-01 |
國立大學法人廣島大學 |
以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
|
|
MX2021012969A
(es)
|
2019-04-24 |
2022-06-09 |
Sanofi Biotechnology |
Metodos de diagnostico y tratamiento de la artritis reumatoide.
|
|
US12492258B2
(en)
|
2019-05-31 |
2025-12-09 |
The Johns Hopkins University |
Bispecific binding agents
|
|
AU2020288561A1
(en)
|
2019-06-04 |
2021-12-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating pain in subjects with rheumatoid arthritis
|
|
JP2022537555A
(ja)
|
2019-06-20 |
2022-08-26 |
武田薬品工業株式会社 |
ウイルスベースの遺伝子療法による治療方法
|
|
CN110483640B
(zh)
*
|
2019-07-16 |
2020-05-01 |
北京汇智和源生物技术有限公司 |
白介素-6r的人源化单克隆抗体、其编码基因及应用
|
|
AU2021231765A1
(en)
|
2020-03-03 |
2022-10-06 |
Redona Therapeutics, Inc. |
Compounds targeting RNA-binding proteins or RNA-modifying proteins
|
|
US20240025991A1
(en)
|
2020-03-23 |
2024-01-25 |
Genentech, Inc. |
Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
|
|
US20230174656A1
(en)
|
2020-03-23 |
2023-06-08 |
Genentech, Inc. |
Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
|
|
EP4107185A1
(en)
|
2020-03-23 |
2022-12-28 |
Genentech, Inc. |
Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
|
|
WO2021211006A1
(en)
|
2020-04-13 |
2021-10-21 |
Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency |
Inhaled hexapeptide for treating interleukin-6 related respiratory diseases
|
|
EP4149421A1
(en)
|
2020-05-15 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in parenteral protein solutions
|
|
WO2021233246A1
(en)
*
|
2020-05-18 |
2021-11-25 |
Biosion Inc. |
Antibodies binding il6r and uses thereof
|
|
WO2022005321A1
(en)
|
2020-06-29 |
2022-01-06 |
Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency |
Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
|
|
KR20220028972A
(ko)
|
2020-08-31 |
2022-03-08 |
(주)셀트리온 |
안정한 약제학적 제제
|
|
JP2023541921A
(ja)
|
2020-09-17 |
2023-10-04 |
ジェネンテック， インコーポレイテッド |
Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
WO2022165419A1
(en)
|
2021-02-01 |
2022-08-04 |
Kyverna Therapeutics, Inc. |
Methods for increasing t-cell function
|
|
MX2023010491A
(es)
|
2021-03-12 |
2023-09-18 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis.
|
|
BR112023025863A2
(pt)
|
2021-06-11 |
2024-03-05 |
Genentech Inc |
Métodos para tratar doença pulmonar obstrutiva crônica (dpoc), para reduzir a frequência de exacerbações moderadas a graves em um paciente com dpoc, para tratar ou prevenir dpoc, para manter e/ou melhorar a função pulmonar, para melhorar a contagem de linha de base de eosinófilos no sangue, kit, antagonistas de st2 e anticorpo anti-st2
|
|
AR127269A1
(es)
|
2021-10-08 |
2024-01-03 |
Chugai Pharmaceutical Co Ltd |
Formulación de anticuerpo anti-hla-dq2.5
|
|
KR20250005335A
(ko)
|
2022-04-26 |
2025-01-09 |
추가이 세이야쿠 가부시키가이샤 |
의약 제제 함유 필터 내장 시린지
|
|
WO2024107752A2
(en)
|
2022-11-15 |
2024-05-23 |
Onestone Therapeutics Llc |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
|
WO2024204671A1
(ja)
|
2023-03-31 |
2024-10-03 |
国立大学法人大阪大学 |
敗血症患者の予後を予測するためのバイオマーカーおよびその使用
|
|
CN121038814A
(zh)
|
2023-04-14 |
2025-11-28 |
中外制药株式会社 |
用于稳定含蛋白质药物制剂的方法
|
|
WO2025198912A1
(en)
|
2024-03-21 |
2025-09-25 |
Hoffmann-La Roche Inc. |
Methods of treating myasthenia gravis
|
|
HUP2400216A1
(hu)
|
2024-04-17 |
2025-10-28 |
Richter Gedeon Nyrt |
N-terminális glutamint tartalmazó immunglobulinok tisztítására szolgáló eljárások
|